Navigation Links
According to Surveyed EU5 Oncologists, Zelboraf Captures 50 Percent Patient Share of the First-Line BRAF-Mutation Positive Malignant Melanoma Population
Date:12/2/2013

EXTON, Pa., Dec. 2, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, according to oncologists surveyed in Q3 2013, Roche/Genentech/Daiichi Sankyo/Chugai's Zelboraf, on average, garners 50 percent patient share across the EU5, in the first-line BRAF-mutation positive setting. In the BRAF-wild-type (BRAF-negative) population, treatment is still dominated by the alkylating agent, dacarbazine (generics). Surveyed oncologists also report that Bristol-Myers Squibb's Yervoy holds, on average, nearly one-third of patient share in second-line BRAF-mutation-positive setting, according to surveyed EU5 oncologists; however, penetration of Yervoy across the EU5 is variable. The vast majority of surveyed respondents cite moderate to high satisfaction with Yervoy and Zelboraf, and surveyed oncologists anticipate a significant increase in first-line prescribing of these agents in BRAF-wild-type and BRAF-mutation-positive malignant melanoma, within the next six months.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO )

According to the data published in the TreatmentTrends® Malignant Melanoma (EU) Q4 2013 report, surveyed EU5 medical oncologists and dermatologists, with the exception of respondents from Spain, report that low-dose Intron A (Merck) garners more patient share than high-dose Intron A as adjuvant treatment for resectable malignant melanoma. High-dose Intron A has significant perceived advantage over low-dose Intron A with respect to efficacy attributes. Conversely, low-dose Intron A has a perceived advantage on safety and tolerability and outperforms high-dose Intron A on experienc
'/>"/>

SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. According to Surveyed U.S. Oncologists, Zelboraf is the Patient Share Leader in First-Line BRAF-Mutation Positive Malignant Melanoma
2. mHealth market is Expected to Reach $58.8 Billion Globally by 2020 According to Allied Market Research Projections
3. More than a Third of Chronic Kidney Disease-Non-Dialysis Patients are Likely Candidates for FG-4592/ASP1517, According to Surveyed EU5 Nephrologists
4. According to Surveyed U.S. Oncologists, Zytiga is the Patient-Share Leader in First-Line Metastatic Castrate-Resistant Prostate Cancer
5. In Terms of Effect on Overall Survival, Current and Emerging Therapies Have No Advantage Over Avastin/FOLFIRI in the Treatment of Second-Line Metastatic Colorectal Cancer, According to Clinical Data and Thought Leader Opinion
6. Rising Drug Resistance is Driving Early-Line Use of Powerful Antibiotics Such as Carbapenems for Gram-Negative Infections, According to Surveyed EU5 Physicians
7. Annual Healthcare Cost for a Typical American Family is $22,030 According to 2013 Milliman Medical Index
8. Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance
9. Fewer Venture Capital Dollars Invested Into Life Sciences Companies In Q1 2013, According To The MoneyTree Report
10. Food Recalls Driven by Companies Issuing Multiple Recalls in the First Quarter of 2013, According to Latest ExpertRECALL Index
11. Nearly 8 Million Healthcare Personnel Come in Contact with Chemotherapy Drugs, According to CDC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... -- Stryker Orthopaedics, the Official Joint Replacement Products of ... its debut year of the relationship at the Charles ... This marks the eleventh tournament stop along both ... has activated on-site with the "Stryker Mobility Zone" – ... importance of joint health.  The Stryker ...
(Date:10/30/2014)... Calif. , Oct. 30, 2014  Electronic ... dramatically as a result of government initiatives and ... - healthcare providers have invested over the past ... heart of health IT, and U.S. clinicians use ... Logo - http://photos.prnewswire.com/prnh/20141029/155278LOGO ...
(Date:10/30/2014)... United Kingdom , Oct. 30, 2014 ... (Nasdaq: CBRX ) and Maryland ... drug developers with improved efficiency during clinical development that ... Diego next week. This partnership ... technologies platform, which it launched earlier this month. The ...
Breaking Medicine Technology:Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 2Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 3Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 4Electronic Health Record Usability: CIOs Weigh In 2Electronic Health Record Usability: CIOs Weigh In 3Electronic Health Record Usability: CIOs Weigh In 4Molecular Profiles To Launch US Strategic Alliance At AAPS 2Molecular Profiles To Launch US Strategic Alliance At AAPS 3
... International Partnership for Microbicides, issued the following statement ... and effectiveness study of BufferGel and PRO2000 (0.5 ... Microbicide Trials Network, a worldwide collaborative group funded ... released final results from its Phase II/IIb safety ...
... Only Approved Platelet Producer in Europe Represents New ... Feb. 6 Amgen (Nasdaq: AMGN ... has granted marketing authorisation for Nplate(R) (romiplostim) for ... thrombocytopenic purpura (ITP) patients who are refractory to ...
Cached Medicine Technology:New PRO2000 HIV-Prevention Findings Important Milestone on Path Toward Development of Effective Vaginal Microbicide 2New PRO2000 HIV-Prevention Findings Important Milestone on Path Toward Development of Effective Vaginal Microbicide 3New PRO2000 HIV-Prevention Findings Important Milestone on Path Toward Development of Effective Vaginal Microbicide 4Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 2Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 3Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 4Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 5Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 6Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 7Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 8
(Date:10/30/2014)... Don Allred Insurance, a leading provider of home, ... Carolina residents, is excited to announce the Grand Opening ... The new branch has been up and running since ... facets of the insurance selection process from quote comparison ... couldn’t be happier with the timing of this Grand ...
(Date:10/30/2014)... OR (PRWEB) October 30, 2014 Five ... firm Hodgkinson Street LLC announces new branding and ... Hodgkinson Street Mepham . After David Mepham’s promotion to ... their brand and website to include Mepham’s name and ... medical malpractice and mediation firm, the decision to implement ...
(Date:10/30/2014)... N.C. (PRWEB) October 30, 2014 Paramount ... health care, is increasing efforts to help people save ... expenses continue to increase for prescription drugs in the ... valuable savings and resources to bridge the relationship between ... One of the biggest challenges people face today with ...
(Date:10/30/2014)... HealthDay Reporter , WEDNESDAY, Oct. 29, ... prostate cancer who also have certain heart problems may increase ... study suggests. , , The therapy in question is called androgen ... levels of male hormones to prevent the growth of cancer ... this hormone therapy was linked to triple the risk of ...
(Date:10/30/2014)... By Dennis Thompson ... -- The Ebola outbreak in Liberia -- one of three ... slowing, World Health Organization officials said Wednesday. Dr. Bruce ... in the number of burials in Liberia and no increase ... the global push to tame the epidemic may be making ...
Breaking Medicine News(10 mins):Health News:Allred Insurance Satellite Office Grand Opening 2Health News:Hodgkinson Street Mepham Rebrands 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 3Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 2Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 3Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 2Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 3
... the Stimulus Bil provide big boost for the conversion to electronic medical ... document scanning and document management systems. , ... Lakewood, CO (PRWEB) March ... to convert their paper records to digital files. Medical record scanning ...
... how precious it really is. 24k gold is a key ingredient in ... , ... York (PRWEB) March 6, 2009 -- While watching CNBC or other major news ... hear that it has kept a rather high value during this economic recession. ...
... continues to impose a huge burden on industrialized societies, ... absence. Annual costs related to back pain in the ... billion per year. , But a systematic review of ... February issue of The Spine Journal finds ...
... first, studies suggest , , THURSDAY, March 5 (HealthDay News) ... effective treatment is a short course of radiation therapy ... , Surgery is the standard treatment for rectal ... of cancer recurrence in the same area, according to ...
... (OTC Bulletin Board: POLGA ; OTC Bulletin Board: ... engineered materials, announced today it will release fourth quarter ... market on Wednesday, March 18, 2009. Company officials will ... at 10:00 a.m. EDT on Thursday, March 19, 2009. ...
... Dr. Steven St. Peter Named to Proteon Board of ... of the world,s largest life sciences-dedicated venture capital investors, ... a $38 million Series B equity financing of Proteon ... of MPM Capital, has been named to the Proteon ...
Cached Medicine News:Health News:Stimulus Package Boosts Medical Document Scanning 2Health News:Gold Not Only Valuable, It's a Healthy Skin Care Ingredient 2Health News:Clinical trials' review finds only exercise to prevent low-back problems 2Health News:Rectal Cancer Outcomes Best With Short-Course Radiation 2Health News:Rectal Cancer Outcomes Best With Short-Course Radiation 3Health News:Polymer Group, Inc. Announces Fourth Quarter and Year-End 2008 Earnings Conference Call 2Health News:MPM Capital Leads Investment in Proteon Therapeutics 2
Iron / TIBC (Ferrozine). Storage temp: 2 - 8 C. Linearity: 0 - 500 ug/dl. Expected values: from TIBC 250 - 400 ug/dl, from Iron 40 - 160 ug/dl. Available with Calibrator and Number of test are 100....
For the quantitative determination of iron, total iron-binding capacity in human serum....
HDL Cholesterol, liquid....
Intended for the quantitative in vitro enzymatic determination of JDL-Cholesterol in human serum or plasma. Two point reaction. Wavelength: 600 nm. Linearity: 1 to 150 mg/dL (0.03 mmol/L to 3.89 mmol...
Medicine Products: